Open AccessThis article is
- freely available
High-Dose Ibuprofen in Cystic Fibrosis
Division of Respiratory Medicine, Montreal Children’s Hospital, D-380, 2300 Tupper Street, Montreal, Quebec, H3H 1P3, Canada
Research Institute of McGill University Health Centre, Montreal Children’s Hospital, C-1223, 2300 Tupper Street, Montreal, Quebec, H3H 1P3, Canada
* Author to whom correspondence should be addressed.
Received: 23 June 2010; in revised form: 6 July 2010 / Accepted: 8 July 2010 / Published: 13 July 2010
Abstract: Cystic Fibrosis (CF) is the most common lethal genetic disorder in North America and Europe. Most patients succumb to progressive lung disease characterized by an exaggerated neutrophilic inflammation. In animal models of chronic infection, high-dose ibuprofen was demonstrated to reduce inflammation without hindering bacterial clearance. This led to two clinical trials, which demonstrated a benefit in slowing the progression of lung disease in CF. However, concerns about potential adverse effects have limited the use of high-dose ibuprofen in CF patients. There are a variety of potential mechanisms to account for the observed clinical benefit. A better understanding of these mechanisms could potentially lead to more targeted and better-tolerated anti-inflammatory therapies.
Keywords: ibuprofen; interleukin-8; neutrophils; cystic fibrosis; CFTR
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Lands, L.C.; Dauletbaev, N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals 2010, 3, 2213-2224.
Lands LC, Dauletbaev N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals. 2010; 3(7):2213-2224.
Lands, Larry C.; Dauletbaev, Nurlan. 2010. "High-Dose Ibuprofen in Cystic Fibrosis." Pharmaceuticals 3, no. 7: 2213-2224.